Patents by Inventor Ralph H. Schwall

Ralph H. Schwall has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MONOVALENT ANTIBODY FRAGMENTS USEFUL AS THERAPEUTICS
    Publication number: 20160222115
    Abstract: The invention provides methods and compositions comprising a novel stabilized monovalent antibody fragment.
    Type: Application
    Filed: April 15, 2016
    Publication date: August 4, 2016
    Applicant: Genentech, Inc.
    Inventors: Arthur Jyh-Yen Huang, Ralph H. Schwall, Daniel G. Yansura
  • MONOVALENT ANTIBODY FRAGMENTS USEFUL AS THERAPEUTICS
    Publication number: 20140205593
    Abstract: The invention provides methods and compositions comprising a novel stabilized monovalent antibody fragment.
    Type: Application
    Filed: April 15, 2013
    Publication date: July 24, 2014
    Applicant: Genentech, Inc.
    Inventors: Arthur Jyh-Yen Huang, Ralph H. Schwall, Daniel G. Yansura
  • ANTIBODY-DRUG CONJUGATES AND METHODS
    Publication number: 20140128580
    Abstract: The present invention relates to antibody-drug conjugate compounds of Formula I: Ab-(L-D)p??I where one or more maytansinoid drug moieties (D) are covalently linked by L to an antibody (Ab) which binds to an ErbB receptor, or which binds to one or more tumor-associated antigens or cell-surface receptors. These compounds may be used in methods of diagnosis or treatment of cancer, and other diseases and disorders.
    Type: Application
    Filed: January 8, 2014
    Publication date: May 8, 2014
    Applicant: Genentech, Inc.
    Inventors: Allen J. Ebens, JR., Frederic S. Jacobson, Paul Polakis, Ralph H. Schwall, Mark X. Sliwkowski, Susan D. Spencer
  • Hepatocyte Growth Factor Receptor Antagonists and Uses Thereof
    Publication number: 20140056921
    Abstract: Hepatocyte growth factor (HGF) receptor antagonists are provided. The HGF receptor antagonists include HGF receptor antibodies and fragments thereof. The HGF receptor antagonists can be employed to block binding of HGF to HGF receptors or substantially inhibit HGF receptor activation. The HGF receptor antagonists may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treating cancer using the HGF receptor antagonists are also provided.
    Type: Application
    Filed: June 6, 2013
    Publication date: February 27, 2014
    Applicant: Genentech, Inc.
    Inventors: Ralph H. Schwall, Kelly H. Tabor
  • HEPATOCYTE GROWTH FACTOR RECEPTOR ANTAGONISTS AND USES THEREOF
    Publication number: 20120321628
    Abstract: Hepatocyte growth factor (HGF) receptor antagonists are provided. The HGF receptor antagonists include HGF receptor antibodies and fragments thereof. The HGF receptor antagonists can be employed to block binding of HGF to HGF receptors or substantially inhibit HGF receptor activation. The HGF receptor antagonists may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treating cancer using the HGF receptor antagonists are also provided.
    Type: Application
    Filed: June 8, 2012
    Publication date: December 20, 2012
    Applicant: Genentech, Inc.
    Inventors: Ralph H. Schwall, Kelly H. Tabor
  • Antibody-drug conjugates and methods
    Patent number: 8142784
    Abstract: The present invention relates to antibody-drug conjugate compounds of Formula I: Ab-(L-D)p??I where one or more maytansinoid drug moieties (D) are covalently linked by L to an antibody (Ab) which binds to an ErbB receptor, or which binds to one or more tumor-associated antigens or cell-surface receptors. These compounds may be used in methods of diagnosis or treatment of cancer, and other diseases and disorders.
    Type: Grant
    Filed: December 2, 2008
    Date of Patent: March 27, 2012
    Assignee: Genentech, Inc.
    Inventors: Allen J. Ebens, Jr., Frederic S. Jacobson, Paul Polakis, Ralph H. Schwall, Mark X. Sliwkowski, Susan D. Spencer
  • HEPATOCYTE GROWTH FACTOR RECEPTOR ANTAGONISTS AND USES THEREOF
    Publication number: 20110280870
    Abstract: Hepatocyte growth factor (HGF) receptor antagonists are provided. The HGF receptor antagonists include HGF receptor antibodies and fragments thereof. The HGF receptor antagonists can be employed to block binding of HGF to HGF receptors or substantially inhibit HGF receptor activation. The HGF receptor antagonists may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treating cancer using the HGF receptor antagonists are also provided.
    Type: Application
    Filed: January 24, 2011
    Publication date: November 17, 2011
    Applicant: Genentech, Inc.
    Inventors: Ralph H. Schwall, Kelly H. Tabor
  • MONOVALENT ANTIBODY FRAGMENTS USEFUL AS THERAPEUTICS
    Publication number: 20110200596
    Abstract: The invention provides methods and compositions comprising a novel stabilized monovalent antibody fragment.
    Type: Application
    Filed: March 10, 2011
    Publication date: August 18, 2011
    Applicant: Genentech, Inc.
    Inventors: Arthur Jyh-Yen Huang, Ralph H. Schwall, Daniel G. Yansura
  • Apo-2 Ligand
    Publication number: 20110183916
    Abstract: A novel cytokine, designated Apo-2 ligand, which induces mammalian cell apoptosis is provided. The Apo-2 ligand is believed to be a member of the TNF cytokine family. Compositions including Apo-2 ligand chimeras, nucleic acid encoding Apo-2 ligand, and antibodies to Apo-2 ligand are also provided. Methods of using Apo-2 ligand to induce apoptosis and to treat pathological conditions such as cancer, are further provided.
    Type: Application
    Filed: September 22, 2010
    Publication date: July 28, 2011
    Applicant: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Ralph H. Schwall
  • ANTIBODY-DRUG CONJUGATES AND METHODS
    Publication number: 20090202536
    Abstract: The present invention relates to antibody-drug conjugate compounds of Formula I: Ab-(L-D)p??I where one or more maytansinoid drug moieties (D) are covalently linked by L to an antibody (Ab) which binds to an ErbB receptor, or which binds to one or more tumor-associated antigens or cell-surface receptors. These compounds may be used in methods of diagnosis or treatment of cancer, and other diseases and disorders.
    Type: Application
    Filed: December 2, 2008
    Publication date: August 13, 2009
    Applicant: Genentech, Inc.
    Inventors: Allen J. Ebens, JR., Frederic S. Jacobson, Paul Polakis, Ralph H. Schwall, Mark X. Sliwkowski, Susan D. Spencer
  • Apo-2 ligand
    Publication number: 20090186812
    Abstract: A novel cytokine, designated Apo-2 ligand, which induces mammalian cell apoptosis is provided. The Apo-2 ligand is believed to be a member of the TNF cytokine family. Compositions including Apo-2 ligand chimeras, nucleic acid encoding Apo-2 ligand, and antibodies to Apo-2 ligand are also provided. Methods of using Apo-2 ligand to induce apoptosis and to treat pathological conditions such as cancer, are further provided.
    Type: Application
    Filed: September 28, 2006
    Publication date: July 23, 2009
    Applicant: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Ralph H. Schwall
  • HEPATOCYTE GROWTH FACTOR RECEPTOR ANTAGONISTS AND USES THEREOF
    Publication number: 20090148457
    Abstract: Hepatocyte growth factor (HGF) receptor antagonists are provided. The HGF receptor antagonists include HGF receptor antibodies and fragments thereof. The HGF receptor antagonists can be employed to block binding of HGF to HGF receptors or substantially inhibit HGF receptor activation. The HGF receptor antagonists may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treating cancer using the HGF receptor antagonists are also provided.
    Type: Application
    Filed: February 4, 2009
    Publication date: June 11, 2009
    Applicant: GENENTECH, INC.
    Inventors: RALPH H. SCHWALL, KELLY H. TABOR
  • Angiogenesis using hepatocyte growth factor
    Publication number: 20080200375
    Abstract: Methods for enhancing angiogenesis in a mammal using hepatocyte growth factor (“HGF”) are provided. In the methods, HGF can be administered to mammals suffering from, for instance, vascular insufficiency or arterial occlusive disease. Articles of manufacture and kits containing HGF are also provided.
    Type: Application
    Filed: May 25, 2006
    Publication date: August 21, 2008
    Applicants: St. Elizabeth's Medical Center of Boston, Inc.
    Inventors: Napoleone Ferrara, Jeffrey M. Isner, Ralph H. Schwall
  • Apo-2 ligand
    Publication number: 20080176788
    Abstract: A novel cytokine, designated Apo-2 ligand, which induces mammalian cell apoptosis is provided. The Apo-2 ligand is believed to be a member of the TNF cytokine family. Compositions including Apo-2 ligand chimeras, nucleic acid encoding Apo-2 ligand, and antibodies to Apo-2 ligand are also provided. Methods of using Apo-2 ligand to induce apoptosis and to treat pathological conditions such as cancer, are further provided.
    Type: Application
    Filed: May 27, 2005
    Publication date: July 24, 2008
    Inventors: Avi J. Ashkenazi, Ralph H. Schwall
  • ANTIBODY-DRUG CONJUGATES AND METHODS
    Publication number: 20080171040
    Abstract: The present invention relates to antibody-drug conjugate compounds of Formula I: Ab-(L-D)pI where one or more maytansinoid drug moieties (D) are covalently linked by L to an antibody (Ab) which binds to an ErbB receptor, or which binds to one or more tumor-associated antigens or cell-surface receptors. These compounds may be used in methods of diagnosis or treatment of cancer, and other diseases and disorders.
    Type: Application
    Filed: March 21, 2008
    Publication date: July 17, 2008
    Applicant: Genentech, Inc.
    Inventors: Allen J. Ebens,, Frederic S. Jacobson, Paul Polakis, Ralph H. Schwall, Mark X. Sliwkowski, Susan D. Spencer
  • Hepatocyte growth factor receptor antagonists and uses thereof
    Publication number: 20030118587
    Abstract: Hepatocyte growth factor (HGF) receptor antagonists are provided. The HGF receptor antagonists include HGF receptor antibodies and fragments thereof. The HGF receptor antagonists can be employed to block binding of HGF to HGF receptors or substantially inhibit HGF receptor activation. The HGF receptor antagonists may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treating cancer using the HGF receptor antagonist are also provided.
    Type: Application
    Filed: September 3, 2002
    Publication date: June 26, 2003
    Inventors: Ralph H. Schwall, Kelly H. Tabor
  • Hepatocyte growth factor receptor antagonists and uses thereof
    Patent number: 6468529
    Abstract: Hepatocyte growth factor (HGF) receptor antagonists are provided. The HGF receptor antagonists include HGF receptor antibodies and fragments thereof. The HGF receptor antagonists can be employed to block binding of HGF to HGF receptors or substantially inhibit HGF receptor activation. The HGF receptor antagonists may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treating cancer using the HGF receptor antagonists are also provided.
    Type: Grant
    Filed: September 26, 2000
    Date of Patent: October 22, 2002
    Assignee: Genentech, Inc.
    Inventors: Ralph H. Schwall, Kelly H. Tabor
  • Hepatocyte growth factor receptor antagonists and uses thereof
    Publication number: 20020136721
    Abstract: Hepatocyte growth factor (HGF) receptor antagonists are provided. The HGF receptor antagonists include HGF receptor antibodies and fragments thereof. The HGF receptor antagonists can be employed to block binding of HGF to HGF receptors or substantially inhibit HGF receptor activation. The HGF receptor antagonists may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treating cancer using the HGF receptor antagonists are also provided.
    Type: Application
    Filed: November 29, 2001
    Publication date: September 26, 2002
    Inventors: Ralph H. Schwall, Kelly H. Tabor
  • Hepatocyte growth factor receptor antagonists and uses thereof
    Patent number: 6214344
    Abstract: Hepatocyte growth factor (HGF) receptor antagonists are provided. The HGF receptor antagonists include HGF receptor antibodies and fragments thereof. The HGF receptor antagonists can be employed to block binding of HGF to HGF receptors or substantially inhibit HGF receptor activation. The HGF receptor antagonists may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treating cancer using the HGF receptor antagonists are also provided.
    Type: Grant
    Filed: January 14, 1998
    Date of Patent: April 10, 2001
    Assignee: Genetech, Inc.
    Inventors: Ralph H. Schwall, Kelly Helen Tabor
  • Hepatocyte growth factor receptor antagonists and uses thereof
    Patent number: 6207152
    Abstract: Hepatocyte growth factor (HGF) receptor antagonists are provided. The HGF receptor antagonists include HGF receptor antibodies and fragments thereof. The HGF receptor antagonists can be employed to block binding of HGF to HGF receptors or substantially inhibit HGF receptor activation. The HGF receptor antagonists may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treating cancer using the HGF receptor antagonists are also provided.
    Type: Grant
    Filed: February 17, 1998
    Date of Patent: March 27, 2001
    Assignee: Genentech, Inc.
    Inventors: Ralph H. Schwall, Kelly H. Tabor